{
    "organizations": [],
    "uuid": "dbf56165aab811d4066e99af8005db6a4474c560",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bristol-myers-squibb-and-illumina/brief-bristol-myers-squibb-and-illumina-announce-collaboration-to-develop-companion-diagnostics-for-bristol-myers-squibbs-oncology-immunotherapies-idUSFWN1RQ0M2",
    "ord_in_thread": 0,
    "title": "BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13, 2018 / 8:31 PM / Updated 8 minutes ago BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies Reuters Staff 1 Min Read \n  Bristol-Myers Squibb Co: \n* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES \n* EXPANDS ILLUMINA’S ONCOLOGY OFFERINGS FOR NEXTSEQ 550DX \n* COS PLAN TO DEVELOP A DIAGNOSTIC VERSION OF ILLUMINA TRUSIGHT ONCOLOGY 500 ASSAY TO MEASURE POTENTIALLY PREDICTIVE GENOMIC BIOMARKERS Source text for Eikon: Further company coverage:",
    "published": "2018-04-13T23:28:00.000+03:00",
    "crawled": "2018-04-13T23:46:36.137+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "squibb",
        "illumina",
        "announce",
        "collaboration",
        "develop",
        "companion",
        "diagnostics",
        "squibb",
        "oncology",
        "immunotherapy",
        "reuters",
        "staff",
        "min",
        "read",
        "squibb",
        "co",
        "squibb",
        "illumina",
        "announce",
        "strategic",
        "collaboration",
        "develop",
        "commercialize",
        "companion",
        "diagnostics",
        "squibb",
        "oncology",
        "immunotherapy",
        "expands",
        "illumina",
        "oncology",
        "offering",
        "nextseq",
        "550dx",
        "co",
        "plan",
        "develop",
        "diagnostic",
        "version",
        "illumina",
        "trusight",
        "oncology",
        "assay",
        "measure",
        "potentially",
        "predictive",
        "genomic",
        "biomarkers",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}